[
    {
        "molecule_name": "Immunoglobulin",
        "protein_target_name": "IL-6",
        "binding_metric": "Kd",
        "value": "<50",
        "unit": "picomolar",
        "is_logarithmic": false,
        "raw_mentions": "The in vitro and in vivo properties of the antibody used in the invention are described in more detail in the examples below and include: having a binding affinity (Kd) for IL-6 of less than about 50 picomolar, and/or a rate of dissociation (K<sub>off</sub>) from IL-6 of less than or equal to 10<sup>-4</sup> S<sup>-1</sup>."
    },
    {
        "molecule_name": "Immunoglobulin",
        "protein_target_name": "IL-6",
        "binding_metric": "Koff",
        "value": "<=10^-4",
        "unit": "S^-1",
        "is_logarithmic": false,
        "raw_mentions": "The in vitro and in vivo properties of the antibody used in the invention are described in more detail in the examples below and include: having a binding affinity (Kd) for IL-6 of less than about 50 picomolar, and/or a rate of dissociation (K<sub>off</sub>) from IL-6 of less than or equal to 10<sup>-4</sup> S<sup>-1</sup>."
    },
    {
        "molecule_name": "Interleukin 6",
        "protein_target_name": "IL-6",
        "binding_metric": "Kd",
        "value": "<=5x10^-7",
        "unit": "M",
        "is_logarithmic": false,
        "raw_mentions": "In one embodiment of the invention, the anti-IL-6 antibodies used in the present invention, bind to IL-6 with a dissociation constant (K<sub>D</sub>) of less than or equal to 5x10<sup>-7</sup>, 10<sup>-7</sup>, 5x10<sup>-8</sup>, 10<sup>-8</sup>, 5x10<sup>-9</sup>, 10<sup>-9</sup>, 5x10<sup>-10</sup>, 10<sup>-10</sup>, 5x10<sup>-11</sup>, 10<sup>-11</sup>, 5x10<sup>-12</sup>, 10<sup>-12</sup>, 5x10<sup>-13</sup>, 10<sup>-13</sup>, 5x10<sup>-14</sup>, 10<sup>-14</sup>, 5x10<sup>-15</sup> or 10<sup>-15</sup>.\nPreferably, the anti-IL-6 antibodies bind IL-6 with a dissociation constant of less than or equal to 5x10<sup>-10</sup>.\nThe anti-IL-6 activity of the anti-IL-6 antibodies bind to IL-6 with an off-rate of less than or equal to 10<sup>-4</sup> S<sup>-1</sup>, 5x10<sup>-5</sup> S<sup>-1</sup>, 10<sup>-5</sup> S<sup>-1</sup>, 5x10<sup>-6</sup> S<sup>-1</sup>, 10<sup>-6</sup> S<sup>-1</sup>, 5x10<sup>-7</sup> S<sup>-1</sup>, or 10<sup>-7</sup> S<sup>-1</sup>."
    },
    {
        "molecule_name": "Interleukin 6",
        "protein_target_name": "IL-6",
        "binding_metric": "Kd",
        "value": "<=10^-7",
        "unit": "M",
        "is_logarithmic": false,
        "raw_mentions": "In one embodiment of the invention, the anti-IL-6 antibodies used in the present invention, bind to IL-6 with a dissociation constant (K<sub>D</sub>) of less than or equal to 5x10<sup>-7</sup>, 10<sup>-7</sup>, 5x10<sup>-8</sup>, 10<sup>-8</sup>, 5x10<sup>-9</sup>, 10<sup>-9</sup>, 5x10<sup>-10</sup>, 10<sup>-10</sup>, 5x10<sup>-11</sup>, 10<sup>-11</sup>, 5x10<sup>-12</sup>, 10<sup>-12</sup>, 5x10<sup>-13</sup>, 10<sup>-13</sup>, 5x10<sup>-14</sup>, 10<sup>-14</sup>, 5x10<sup>-15</sup> or 10<sup>-15</sup>.\nPreferably, the anti-IL-6 antibodies bind IL-6 with a dissociation constant of less than or equal to 5x10<sup>-10</sup>.\nThe anti-IL-6 activity of the anti-IL-6 antibodies bind to IL-6 with an off-rate of less than or equal to 10<sup>-4</sup> S<sup>-1</sup>, 5x10<sup>-5</sup> S<sup>-1</sup>, 10<sup>-5</sup> S<sup>-1</sup>, 5x10<sup>-6</sup> S<sup>-1</sup>, 10<sup>-6</sup> S<sup>-1</sup>, 5x10<sup>-7</sup> S<sup>-1</sup>, or 10<sup>-7</sup> S<sup>-1</sup>."
    },
    {
        "molecule_name": "Interleukin 6",
        "protein_target_name": "IL-6",
        "binding_metric": "Kd",
        "value": "<=5x10^-8",
        "unit": "M",
        "is_logarithmic": false,
        "raw_mentions": "In one embodiment of the invention, the anti-IL-6 antibodies used in the present invention, bind to IL-6 with a dissociation constant (K<sub>D</sub>) of less than or equal to 5x10<sup>-7</sup>, 10<sup>-7</sup>, 5x10<sup>-8</sup>, 10<sup>-8</sup>, 5x10<sup>-9</sup>, 10<sup>-9</sup>, 5x10<sup>-10</sup>, 10<sup>-10</sup>, 5x10<sup>-11</sup>, 10<sup>-11</sup>, 5x10<sup>-12</sup>, 10<sup>-12</sup>, 5x10<sup>-13</sup>, 10<sup>-13</sup>, 5x10<sup>-14</sup>, 10<sup>-14</sup>, 5x10<sup>-15</sup> or 10<sup>-15</sup>.\nPreferably, the anti-IL-6 antibodies bind IL-6 with a dissociation constant of less than or equal to 5x10<sup>-10</sup>.\nThe anti-IL-6 activity of the anti-IL-6 antibodies bind to IL-6 with an off-rate of less than or equal to 10<sup>-4</sup> S<sup>-1</sup>, 5x10<sup>-5</sup> S<sup>-1</sup>, 10<sup>-5</sup> S<sup>-1</sup>, 5x10<sup>-6</sup> S<sup>-1</sup>, 10<sup>-6</sup> S<sup>-1</sup>, 5x10<sup>-7</sup> S<sup>-1</sup>, or 10<sup>-7</sup> S<sup>-1</sup>."
    },
    {
        "molecule_name": "Interleukin 6",
        "protein_target_name": "IL-6",
        "binding_metric": "Kd",
        "value": "<=10^-8",
        "unit": "M",
        "is_logarithmic": false,
        "raw_mentions": "In one embodiment of the invention, the anti-IL-6 antibodies used in the present invention, bind to IL-6 with a dissociation constant (K<sub>D</sub>) of less than or equal to 5x10<sup>-7</sup>, 10<sup>-7</sup>, 5x10<sup>-8</sup>, 10<sup>-8</sup>, 5x10<sup>-9</sup>, 10<sup>-9</sup>, 5x10<sup>-10</sup>, 10<sup>-10</sup>, 5x10<sup>-11</sup>, 10<sup>-11</sup>, 5x10<sup>-12</sup>, 10<sup>-12</sup>, 5x10<sup>-13</sup>, 10<sup>-13</sup>, 5x10<sup>-14</sup>, 10<sup>-14</sup>, 5x10<sup>-15</sup> or 10<sup>-15</sup>.\nPreferably, the anti-IL-6 antibodies bind IL-6 with a dissociation constant of less than or equal to 5x10<sup>-10</sup>.\nThe anti-IL-6 activity of the anti-IL-6 antibodies bind to IL-6 with an off-rate of less than or equal to 10<sup>-4</sup> S<sup>-1</sup>, 5x10<sup>-5</sup> S<sup>-1</sup>, 10<sup>-5</sup> S<sup>-1</sup>, 5x10<sup>-6</sup> S<sup>-1</sup>, 10<sup>-6</sup> S<sup>-1</sup>, 5x10<sup>-7</sup> S<sup>-1</sup>, or 10<sup>-7</sup> S<sup>-1</sup>."
    },
    {
        "molecule_name": "Interleukin 6",
        "protein_target_name": "IL-6",
        "binding_metric": "Kd",
        "value": "<=5x10^-9",
        "unit": "M",
        "is_logarithmic": false,
        "raw_mentions": "In one embodiment of the invention, the anti-IL-6 antibodies used in the present invention, bind to IL-6 with a dissociation constant (K<sub>D</sub>) of less than or equal to 5x10<sup>-7</sup>, 10<sup>-7</sup>, 5x10<sup>-8</sup>, 10<sup>-8</sup>, 5x10<sup>-9</sup>, 10<sup>-9</sup>, 5x10<sup>-10</sup>, 10<sup>-10</sup>, 5x10<sup>-11</sup>, 10<sup>-11</sup>, 5x10<sup>-12</sup>, 10<sup>-12</sup>, 5x10<sup>-13</sup>, 10<sup>-13</sup>, 5x10<sup>-14</sup>, 10<sup>-14</sup>, 5x10<sup>-15</sup> or 10<sup>-15</sup>.\nPreferably, the anti-IL-6 antibodies bind IL-6 with a dissociation constant of less than or equal to 5x10<sup>-10</sup>.\nThe anti-IL-6 activity of the anti-IL-6 antibodies bind to IL-6 with an off-rate of less than or equal to 10<sup>-4</sup> S<sup>-1</sup>, 5x10<sup>-5</sup> S<sup>-1</sup>, 10<sup>-5</sup> S<sup>-1</sup>, 5x10<sup>-6</sup> S<sup>-1</sup>, 10<sup>-6</sup> S<sup>-1</sup>, 5x10<sup>-7</sup> S<sup>-1</sup>, or 10<sup>-7</sup> S<sup>-1</sup>."
    },
    {
        "molecule_name": "Interleukin 6",
        "protein_target_name": "IL-6",
        "binding_metric": "Kd",
        "value": "<=10^-9",
        "unit": "M",
        "is_logarithmic": false,
        "raw_mentions": "In one embodiment of the invention, the anti-IL-6 antibodies used in the present invention, bind to IL-6 with a dissociation constant (K<sub>D</sub>) of less than or equal to 5x10<sup>-7</sup>, 10<sup>-7</sup>, 5x10<sup>-8</sup>, 10<sup>-8</sup>, 5x10<sup>-9</sup>, 10<sup>-9</sup>, 5x10<sup>-10</sup>, 10<sup>-10</sup>, 5x10<sup>-11</sup>, 10<sup>-11</sup>, 5x10<sup>-12</sup>, 10<sup>-12</sup>, 5x10<sup>-13</sup>, 10<sup>-13</sup>, 5x10<sup>-14</sup>, 10<sup>-14</sup>, 5x10<sup>-15</sup> or 10<sup>-15</sup>.\nPreferably, the anti-IL-6 antibodies bind IL-6 with a dissociation constant of less than or equal to 5x10<sup>-10</sup>.\nThe anti-IL-6 activity of the anti-IL-6 antibodies bind to IL-6 with an off-rate of less than or equal to 10<sup>-4</sup> S<sup>-1</sup>, 5x10<sup>-5</sup> S<sup>-1</sup>, 10<sup>-5</sup> S<sup>-1</sup>, 5x10<sup>-6</sup> S<sup>-1</sup>, 10<sup>-6</sup> S<sup>-1</sup>, 5x10<sup>-7</sup> S<sup>-1</sup>, or 10<sup>-7</sup> S<sup>-1</sup>."
    },
    {
        "molecule_name": "Interleukin 6",
        "protein_target_name": "IL-6",
        "binding_metric": "Kd",
        "value": "<=5x10^-10",
        "unit": "M",
        "is_logarithmic": false,
        "raw_mentions": "In one embodiment of the invention, the anti-IL-6 antibodies used in the present invention, bind to IL-6 with a dissociation constant (K<sub>D</sub>) of less than or equal to 5x10<sup>-7</sup>, 10<sup>-7</sup>, 5x10<sup>-8</sup>, 10<sup>-8</sup>, 5x10<sup>-9</sup>, 10<sup>-9</sup>, 5x10<sup>-10</sup>, 10<sup>-10</sup>, 5x10<sup>-11</sup>, 10<sup>-11</sup>, 5x10<sup>-12</sup>, 10<sup>-12</sup>, 5x10<sup>-13</sup>, 10<sup>-13</sup>, 5x10<sup>-14</sup>, 10<sup>-14</sup>, 5x10<sup>-15</sup> or 10<sup>-15</sup>.\nPreferably, the anti-IL-6 antibodies bind IL-6 with a dissociation constant of less than or equal to 5x10<sup>-10</sup>.\nThe anti-IL-6 activity of the anti-IL-6 antibodies bind to IL-6 with an off-rate of less than or equal to 10<sup>-4</sup> S<sup>-1</sup>, 5x10<sup>-5</sup> S<sup>-1</sup>, 10<sup>-5</sup> S<sup>-1</sup>, 5x10<sup>-6</sup> S<sup>-1</sup>, 10<sup>-6</sup> S<sup>-1</sup>, 5x10<sup>-7</sup> S<sup>-1</sup>, or 10<sup>-7</sup> S<sup>-1</sup>."
    },
    {
        "molecule_name": "Interleukin 6",
        "protein_target_name": "IL-6",
        "binding_metric": "Kd",
        "value": "<=10^-10",
        "unit": "M",
        "is_logarithmic": false,
        "raw_mentions": "In one embodiment of the invention, the anti-IL-6 antibodies used in the present invention, bind to IL-6 with a dissociation constant (K<sub>D</sub>) of less than or equal to 5x10<sup>-7</sup>, 10<sup>-7</sup>, 5x10<sup>-8</sup>, 10<sup>-8</sup>, 5x10<sup>-9</sup>, 10<sup>-9</sup>, 5x10<sup>-10</sup>, 10<sup>-10</sup>, 5x10<sup>-11</sup>, 10<sup>-11</sup>, 5x10<sup>-12</sup>, 10<sup>-12</sup>, 5x10<sup>-13</sup>, 10<sup>-13</sup>, 5x10<sup>-14</sup>, 10<sup>-14</sup>, 5x10<sup>-15</sup> or 10<sup>-15</sup>.\nPreferably, the anti-IL-6 antibodies bind IL-6 with a dissociation constant of less than or equal to 5x10<sup>-10</sup>.\nThe anti-IL-6 activity of the anti-IL-6 antibodies bind to IL-6 with an off-rate of less than or equal to 10<sup>-4</sup> S<sup>-1</sup>, 5x10<sup>-5</sup> S<sup>-1</sup>, 10<sup>-5</sup> S<sup>-1</sup>, 5x10<sup>-6</sup> S<sup>-1</sup>, 10<sup>-6</sup> S<sup>-1</sup>, 5x10<sup>-7</sup> S<sup>-1</sup>, or 10<sup>-7</sup> S<sup>-1</sup>."
    },
    {
        "molecule_name": "Interleukin 6",
        "protein_target_name": "IL-6",
        "binding_metric": "Kd",
        "value": "<=5x10^-11",
        "unit": "M",
        "is_logarithmic": false,
        "raw_mentions": "In one embodiment of the invention, the anti-IL-6 antibodies used in the present invention, bind to IL-6 with a dissociation constant (K<sub>D</sub>) of less than or equal to 5x10<sup>-7</sup>, 10<sup>-7</sup>, 5x10<sup>-8</sup>, 10<sup>-8</sup>, 5x10<sup>-9</sup>, 10<sup>-9</sup>, 5x10<sup>-10</sup>, 10<sup>-10</sup>, 5x10<sup>-11</sup>, 10<sup>-11</sup>, 5x10<sup>-12</sup>, 10<sup>-12</sup>, 5x10<sup>-13</sup>, 10<sup>-13</sup>, 5x10<sup>-14</sup>, 10<sup>-14</sup>, 5x10<sup>-15</sup> or 10<sup>-15</sup>.\nPreferably, the anti-IL-6 antibodies bind IL-6 with a dissociation constant of less than or equal to 5x10<sup>-10</sup>.\nThe anti-IL-6 activity of the anti-IL-6 antibodies bind to IL-6 with an off-rate of less than or equal to 10<sup>-4</sup> S<sup>-1</sup>, 5x10<sup>-5</sup> S<sup>-1</sup>, 10<sup>-5</sup> S<sup>-1</sup>, 5x10<sup>-6</sup> S<sup>-1</sup>, 10<sup>-6</sup> S<sup>-1</sup>, 5x10<sup>-7</sup> S<sup>-1</sup>, or 10<sup>-7</sup> S<sup>-1</sup>."
    },
    {
        "molecule_name": "Interleukin 6",
        "protein_target_name": "IL-6",
        "binding_metric": "Kd",
        "value": "<=10^-11",
        "unit": "M",
        "is_logarithmic": false,
        "raw_mentions": "In one embodiment of the invention, the anti-IL-6 antibodies used in the present invention, bind to IL-6 with a dissociation constant (K<sub>D</sub>) of less than or equal to 5x10<sup>-7</sup>, 10<sup>-7</sup>, 5x10<sup>-8</sup>, 10<sup>-8</sup>, 5x10<sup>-9</sup>, 10<sup>-9</sup>, 5x10<sup>-10</sup>, 10<sup>-10</sup>, 5x10<sup>-11</sup>, 10<sup>-11</sup>, 5x10<sup>-12</sup>, 10<sup>-12</sup>, 5x10<sup>-13</sup>, 10<sup>-13</sup>, 5x10<sup>-14</sup>, 10<sup>-14</sup>, 5x10<sup>-15</sup> or 10<sup>-15</sup>.\nPreferably, the anti-IL-6 antibodies bind IL-6 with a dissociation constant of less than or equal to 5x10<sup>-10</sup>.\nThe anti-IL-6 activity of the anti-IL-6 antibodies bind to IL-6 with an off-rate of less than or equal to 10<sup>-4</sup> S<sup>-1</sup>, 5x10<sup>-5</sup> S<sup>-1</sup>, 10<sup>-5</sup> S<sup>-1</sup>, 5x10<sup>-6</sup> S<sup>-1</sup>, 10<sup>-6</sup> S<sup>-1</sup>, 5x10<sup>-7</sup> S<sup>-1</sup>, or 10<sup>-7</sup> S<sup>-1</sup>."
    },
    {
        "molecule_name": "Interleukin 6",
        "protein_target_name": "IL-6",
        "binding_metric": "Kd",
        "value": "<=5x10^-12",
        "unit": "M",
        "is_logarithmic": false,
        "raw_mentions": "In one embodiment of the invention, the anti-IL-6 antibodies used in the present invention, bind to IL-6 with a dissociation constant (K<sub>D</sub>) of less than or equal to 5x10<sup>-7</sup>, 10<sup>-7</sup>, 5x10<sup>-8</sup>, 10<sup>-8</sup>, 5x10<sup>-9</sup>, 10<sup>-9</sup>, 5x10<sup>-10</sup>, 10<sup>-10</sup>, 5x10<sup>-11</sup>, 10<sup>-11</sup>, 5x10<sup>-12</sup>, 10<sup>-12</sup>, 5x10<sup>-13</sup>, 10<sup>-13</sup>, 5x10<sup>-14</sup>, 10<sup>-14</sup>, 5x10<sup>-15</sup> or 10<sup>-15</sup>.\nPreferably, the anti-IL-6 antibodies bind IL-6 with a dissociation constant of less than or equal to 5x10<sup>-10</sup>.\nThe anti-IL-6 activity of the anti-IL-6 antibodies bind to IL-6 with an off-rate of less than or equal to 10<sup>-4</sup> S<sup>-1</sup>, 5x10<sup>-5</sup> S<sup>-1</sup>, 10<sup>-5</sup> S<sup>-1</sup>, 5x10<sup>-6</sup> S<sup>-1</sup>, 10<sup>-6</sup> S<sup>-1</sup>, 5x10<sup>-7</sup> S<sup>-1</sup>, or 10<sup>-7</sup> S<sup>-1</sup>."
    },
    {
        "molecule_name": "Interleukin 6",
        "protein_target_name": "IL-6",
        "binding_metric": "Kd",
        "value": "<=10^-12",
        "unit": "M",
        "is_logarithmic": false,
        "raw_mentions": "In one embodiment of the invention, the anti-IL-6 antibodies used in the present invention, bind to IL-6 with a dissociation constant (K<sub>D</sub>) of less than or equal to 5x10<sup>-7</sup>, 10<sup>-7</sup>, 5x10<sup>-8</sup>, 10<sup>-8</sup>, 5x10<sup>-9</sup>, 10<sup>-9</sup>, 5x10<sup>-10</sup>, 10<sup>-10</sup>, 5x10<sup>-11</sup>, 10<sup>-11</sup>, 5x10<sup>-12</sup>, 10<sup>-12</sup>, 5x10<sup>-13</sup>, 10<sup>-13</sup>, 5x10<sup>-14</sup>, 10<sup>-14</sup>, 5x10<sup>-15</sup> or 10<sup>-15</sup>.\nPreferably, the anti-IL-6 antibodies bind IL-6 with a dissociation constant of less than or equal to 5x10<sup>-10</sup>.\nThe anti-IL-6 activity of the anti-IL-6 antibodies bind to IL-6 with an off-rate of less than or equal to 10<sup>-4</sup> S<sup>-1</sup>, 5x10<sup>-5</sup> S<sup>-1</sup>, 10<sup>-5</sup> S<sup>-1</sup>, 5x10<sup>-6</sup> S<sup>-1</sup>, 10<sup>-6</sup> S<sup>-1</sup>, 5x10<sup>-7</sup> S<sup>-1</sup>, or 10<sup>-7</sup> S<sup>-1</sup>."
    },
    {
        "molecule_name": "Interleukin 6",
        "protein_target_name": "IL-6",
        "binding_metric": "Kd",
        "value": "<=5x10^-13",
        "unit": "M",
        "is_logarithmic": false,
        "raw_mentions": "In one embodiment of the invention, the anti-IL-6 antibodies used in the present invention, bind to IL-6 with a dissociation constant (K<sub>D</sub>) of less than or equal to 5x10<sup>-7</sup>, 10<sup>-7</sup>, 5x10<sup>-8</sup>, 10<sup>-8</sup>, 5x10<sup>-9</sup>, 10<sup>-9</sup>, 5x10<sup>-10</sup>, 10<sup>-10</sup>, 5x10<sup>-11</sup>, 10<sup>-11</sup>, 5x10<sup>-12</sup>, 10<sup>-12</sup>, 5x10<sup>-13</sup>, 10<sup>-13</sup>, 5x10<sup>-14</sup>, 10<sup>-14</sup>, 5x10<sup>-15</sup> or 10<sup>-15</sup>.\nPreferably, the anti-IL-6 antibodies bind IL-6 with a dissociation constant of less than or equal to 5x10<sup>-10</sup>.\nThe anti-IL-6 activity of the anti-IL-6 antibodies bind to IL-6 with an off-rate of less than or equal to 10<sup>-4</sup> S<sup>-1</sup>, 5x10<sup>-5</sup> S<sup>-1</sup>, 10<sup>-5</sup> S<sup>-1</sup>, 5x10<sup>-6</sup> S<sup>-1</sup>, 10<sup>-6</sup> S<sup>-1</sup>, 5x10<sup>-7</sup> S<sup>-1</sup>, or 10<sup>-7</sup> S<sup>-1</sup>."
    },
    {
        "molecule_name": "Interleukin 6",
        "protein_target_name": "IL-6",
        "binding_metric": "Kd",
        "value": "<=10^-13",
        "unit": "M",
        "is_logarithmic": false,
        "raw_mentions": "In one embodiment of the invention, the anti-IL-6 antibodies used in the present invention, bind to IL-6 with a dissociation constant (K<sub>D</sub>) of less than or equal to 5x10<sup>-7</sup>, 10<sup>-7</sup>, 5x10<sup>-8</sup>, 10<sup>-8</sup>, 5x10<sup>-9</sup>, 10<sup>-9</sup>, 5x10<sup>-10</sup>, 10<sup>-10</sup>, 5x10<sup>-11</sup>, 10<sup>-11</sup>, 5x10<sup>-12</sup>, 10<sup>-12</sup>, 5x10<sup>-13</sup>, 10<sup>-13</sup>, 5x10<sup>-14</sup>, 10<sup>-14</sup>, 5x10<sup>-15</sup> or 10<sup>-15</sup>.\nPreferably, the anti-IL-6 antibodies bind IL-6 with a dissociation constant of less than or equal to 5x10<sup>-10</sup>.\nThe anti-IL-6 activity of the anti-IL-6 antibodies bind to IL-6 with an off-rate of less than or equal to 10<sup>-4</sup> S<sup>-1</sup>, 5x10<sup>-5</sup> S<sup>-1</sup>, 10<sup>-5</sup> S<sup>-1</sup>, 5x10<sup>-6</sup> S<sup>-1</sup>, 10<sup>-6</sup> S<sup>-1</sup>, 5x10<sup>-7</sup> S<sup>-1</sup>, or 10<sup>-7</sup> S<sup>-1</sup>."
    },
    {
        "molecule_name": "Interleukin 6",
        "protein_target_name": "IL-6",
        "binding_metric": "Kd",
        "value": "<=5x10^-14",
        "unit": "M",
        "is_logarithmic": false,
        "raw_mentions": "In one embodiment of the invention, the anti-IL-6 antibodies used in the present invention, bind to IL-6 with a dissociation constant (K<sub>D</sub>) of less than or equal to 5x10<sup>-7</sup>, 10<sup>-7</sup>, 5x10<sup>-8</sup>, 10<sup>-8</sup>, 5x10<sup>-9</sup>, 10<sup>-9</sup>, 5x10<sup>-10</sup>, 10<sup>-10</sup>, 5x10<sup>-11</sup>, 10<sup>-11</sup>, 5x10<sup>-12</sup>, 10<sup>-12</sup>, 5x10<sup>-13</sup>, 10<sup>-13</sup>, 5x10<sup>-14</sup>, 10<sup>-14</sup>, 5x10<sup>-15</sup> or 10<sup>-15</sup>.\nPreferably, the anti-IL-6 antibodies bind IL-6 with a dissociation constant of less than or equal to 5x10<sup>-10</sup>.\nThe anti-IL-6 activity of the anti-IL-6 antibodies bind to IL-6 with an off-rate of less than or equal to 10<sup>-4</sup> S<sup>-1</sup>, 5x10<sup>-5</sup> S<sup>-1</sup>, 10<sup>-5</sup> S<sup>-1</sup>, 5x10<sup>-6</sup> S<sup>-1</sup>, 10<sup>-6</sup> S<sup>-1</sup>, 5x10<sup>-7</sup> S<sup>-1</sup>, or 10<sup>-7</sup> S<sup>-1</sup>."
    },
    {
        "molecule_name": "Interleukin 6",
        "protein_target_name": "IL-6",
        "binding_metric": "Kd",
        "value": "<=10^-14",
        "unit": "M",
        "is_logarithmic": false,
        "raw_mentions": "In one embodiment of the invention, the anti-IL-6 antibodies used in the present invention, bind to IL-6 with a dissociation constant (K<sub>D</sub>) of less than or equal to 5x10<sup>-7</sup>, 10<sup>-7</sup>, 5x10<sup>-8</sup>, 10<sup>-8</sup>, 5x10<sup>-9</sup>, 10<sup>-9</sup>, 5x10<sup>-10</sup>, 10<sup>-10</sup>, 5x10<sup>-11</sup>, 10<sup>-11</sup>, 5x10<sup>-12</sup>, 10<sup>-12</sup>, 5x10<sup>-13</sup>, 10<sup>-13</sup>, 5x10<sup>-14</sup>, 10<sup>-14</sup>, 5x10<sup>-15</sup> or 10<sup>-15</sup>.\nPreferably, the anti-IL-6 antibodies bind IL-6 with a dissociation constant of less than or equal to 5x10<sup>-10</sup>.\nThe anti-IL-6 activity of the anti-IL-6 antibodies bind to IL-6 with an off-rate of less than or equal to 10<sup>-4</sup> S<sup>-1</sup>, 5x10<sup>-5</sup> S<sup>-1</sup>, 10<sup>-5</sup> S<sup>-1</sup>, 5x10<sup>-6</sup> S<sup>-1</sup>, 10<sup>-6</sup> S<sup>-1</sup>, 5x10<sup>-7</sup> S<sup>-1</sup>, or 10<sup>-7</sup> S<sup>-1</sup>."
    },
    {
        "molecule_name": "Interleukin 6",
        "protein_target_name": "IL-6",
        "binding_metric": "Kd",
        "value": "<=5x10^-15",
        "unit": "M",
        "is_logarithmic": false,
        "raw_mentions": "In one embodiment of the invention, the anti-IL-6 antibodies used in the present invention, bind to IL-6 with a dissociation constant (K<sub>D</sub>) of less than or equal to 5x10<sup>-7</sup>, 10<sup>-7</sup>, 5x10<sup>-8</sup>, 10<sup>-8</sup>, 5x10<sup>-9</sup>, 10<sup>-9</sup>, 5x10<sup>-10</sup>, 10<sup>-10</sup>, 5x10<sup>-11</sup>, 10<sup>-11</sup>, 5x10<sup>-12</sup>, 10<sup>-12</sup>, 5x10<sup>-13</sup>, 10<sup>-13</sup>, 5x10<sup>-14</sup>, 10<sup>-14</sup>, 5x10<sup>-15</sup> or 10<sup>-15</sup>.\nPreferably, the anti-IL-6 antibodies bind IL-6 with a dissociation constant of less than or equal to 5x10<sup>-10</sup>.\nThe anti-IL-6 activity of the anti-IL-6 antibodies bind to IL-6 with an off-rate of less than or equal to 10<sup>-4</sup> S<sup>-1</sup>, 5x10<sup>-5</sup> S<sup>-1</sup>, 10<sup>-5</sup> S<sup>-1</sup>, 5x10<sup>-6</sup> S<sup>-1</sup>, 10<sup>-6</sup> S<sup>-1</sup>, 5x10<sup>-7</sup> S<sup>-1</sup>, or 10<sup>-7</sup> S<sup>-1</sup>."
    },
    {
        "molecule_name": "Interleukin 6",
        "protein_target_name": "IL-6",
        "binding_metric": "Kd",
        "value": "<=10^-15",
        "unit": "M",
        "is_logarithmic": false,
        "raw_mentions": "In one embodiment of the invention, the anti-IL-6 antibodies used in the present invention, bind to IL-6 with a dissociation constant (K<sub>D</sub>) of less than or equal to 5x10<sup>-7</sup>, 10<sup>-7</sup>, 5x10<sup>-8</sup>, 10<sup>-8</sup>, 5x10<sup>-9</sup>, 10<sup>-9</sup>, 5x10<sup>-10</sup>, 10<sup>-10</sup>, 5x10<sup>-11</sup>, 10<sup>-11</sup>, 5x10<sup>-12</sup>, 10<sup>-12</sup>, 5x10<sup>-13</sup>, 10<sup>-13</sup>, 5x10<sup>-14</sup>, 10<sup>-14</sup>, 5x10<sup>-15</sup> or 10<sup>-15</sup>.\nPreferably, the anti-IL-6 antibodies bind IL-6 with a dissociation constant of less than or equal to 5x10<sup>-10</sup>.\nThe anti-IL-6 activity of the anti-IL-6 antibodies bind to IL-6 with an off-rate of less than or equal to 10<sup>-4</sup> S<sup>-1</sup>, 5x10<sup>-5</sup> S<sup>-1</sup>, 10<sup>-5</sup> S<sup>-1</sup>, 5x10<sup>-6</sup> S<sup>-1</sup>, 10<sup>-6</sup> S<sup>-1</sup>, 5x10<sup>-7</sup> S<sup>-1</sup>, or 10<sup>-7</sup> S<sup>-1</sup>."
    },
    {
        "molecule_name": "Interleukin 6",
        "protein_target_name": "IL-6",
        "binding_metric": "Kd",
        "value": "<=5x10^-10",
        "unit": "M",
        "is_logarithmic": false,
        "raw_mentions": "In one embodiment of the invention, the anti-IL-6 antibodies used in the present invention, bind to IL-6 with a dissociation constant (K<sub>D</sub>) of less than or equal to 5x10<sup>-7</sup>, 10<sup>-7</sup>, 5x10<sup>-8</sup>, 10<sup>-8</sup>, 5x10<sup>-9</sup>, 10<sup>-9</sup>, 5x10<sup>-10</sup>, 10<sup>-10</sup>, 5x10<sup>-11</sup>, 10<sup>-11</sup>, 5x10<sup>-12</sup>, 10<sup>-12</sup>, 5x10<sup>-13</sup>, 10<sup>-13</sup>, 5x10<sup>-14</sup>, 10<sup>-14</sup>, 5x10<sup>-15</sup> or 10<sup>-15</sup>.\nPreferably, the anti-IL-6 antibodies bind IL-6 with a dissociation constant of less than or equal to 5x10<sup>-10</sup>.\nThe anti-IL-6 activity of the anti-IL-6 antibodies bind to IL-6 with an off-rate of less than or equal to 10<sup>-4</sup> S<sup>-1</sup>, 5x10<sup>-5</sup> S<sup>-1</sup>, 10<sup>-5</sup> S<sup>-1</sup>, 5x10<sup>-6</sup> S<sup>-1</sup>, 10<sup>-6</sup> S<sup>-1</sup>, 5x10<sup>-7</sup> S<sup>-1</sup>, or 10<sup>-7</sup> S<sup>-1</sup>."
    },
    {
        "molecule_name": "Interleukin 6",
        "protein_target_name": "IL-6",
        "binding_metric": "off-rate",
        "value": "<=10^-4",
        "unit": "S^-1",
        "is_logarithmic": false,
        "raw_mentions": "In one embodiment of the invention, the anti-IL-6 antibodies used in the present invention, bind to IL-6 with a dissociation constant (K<sub>D</sub>) of less than or equal to 5x10<sup>-7</sup>, 10<sup>-7</sup>, 5x10<sup>-8</sup>, 10<sup>-8</sup>, 5x10<sup>-9</sup>, 10<sup>-9</sup>, 5x10<sup>-10</sup>, 10<sup>-10</sup>, 5x10<sup>-11</sup>, 10<sup>-11</sup>, 5x10<sup>-12</sup>, 10<sup>-12</sup>, 5x10<sup>-13</sup>, 10<sup>-13</sup>, 5x10<sup>-14</sup>, 10<sup>-14</sup>, 5x10<sup>-15</sup> or 10<sup>-15</sup>.\nPreferably, the anti-IL-6 antibodies bind IL-6 with a dissociation constant of less than or equal to 5x10<sup>-10</sup>.\nThe anti-IL-6 activity of the anti-IL-6 antibodies bind to IL-6 with an off-rate of less than or equal to 10<sup>-4</sup> S<sup>-1</sup>, 5x10<sup>-5</sup> S<sup>-1</sup>, 10<sup>-5</sup> S<sup>-1</sup>, 5x10<sup>-6</sup> S<sup>-1</sup>, 10<sup>-6</sup> S<sup>-1</sup>, 5x10<sup>-7</sup> S<sup>-1</sup>, or 10<sup>-7</sup> S<sup>-1</sup>."
    },
    {
        "molecule_name": "Interleukin 6",
        "protein_target_name": "IL-6",
        "binding_metric": "off-rate",
        "value": "<=5x10^-5",
        "unit": "S^-1",
        "is_logarithmic": false,
        "raw_mentions": "In one embodiment of the invention, the anti-IL-6 antibodies used in the present invention, bind to IL-6 with a dissociation constant (K<sub>D</sub>) of less than or equal to 5x10<sup>-7</sup>, 10<sup>-7</sup>, 5x10<sup>-8</sup>, 10<sup>-8</sup>, 5x10<sup>-9</sup>, 10<sup>-9</sup>, 5x10<sup>-10</sup>, 10<sup>-10</sup>, 5x10<sup>-11</sup>, 10<sup>-11</sup>, 5x10<sup>-12</sup>, 10<sup>-12</sup>, 5x10<sup>-13</sup>, 10<sup>-13</sup>, 5x10<sup>-14</sup>, 10<sup>-14</sup>, 5x10<sup>-15</sup> or 10<sup>-15</sup>.\nPreferably, the anti-IL-6 antibodies bind IL-6 with a dissociation constant of less than or equal to 5x10<sup>-10</sup>.\nThe anti-IL-6 activity of the anti-IL-6 antibodies bind to IL-6 with an off-rate of less than or equal to 10<sup>-4</sup> S<sup>-1</sup>, 5x10<sup>-5</sup> S<sup>-1</sup>, 10<sup>-5</sup> S<sup>-1</sup>, 5x10<sup>-6</sup> S<sup>-1</sup>, 10<sup>-6</sup> S<sup>-1</sup>, 5x10<sup>-7</sup> S<sup>-1</sup>, or 10<sup>-7</sup> S<sup>-1</sup>."
    },
    {
        "molecule_name": "Interleukin 6",
        "protein_target_name": "IL-6",
        "binding_metric": "off-rate",
        "value": "<=10^-5",
        "unit": "S^-1",
        "is_logarithmic": false,
        "raw_mentions": "In one embodiment of the invention, the anti-IL-6 antibodies used in the present invention, bind to IL-6 with a dissociation constant (K<sub>D</sub>) of less than or equal to 5x10<sup>-7</sup>, 10<sup>-7</sup>, 5x10<sup>-8</sup>, 10<sup>-8</sup>, 5x10<sup>-9</sup>, 10<sup>-9</sup>, 5x10<sup>-10</sup>, 10<sup>-10</sup>, 5x10<sup>-11</sup>, 10<sup>-11</sup>, 5x10<sup>-12</sup>, 10<sup>-12</sup>, 5x10<sup>-13</sup>, 10<sup>-13</sup>, 5x10<sup>-14</sup>, 10<sup>-14</sup>, 5x10<sup>-15</sup> or 10<sup>-15</sup>.\nPreferably, the anti-IL-6 antibodies bind IL-6 with a dissociation constant of less than or equal to 5x10<sup>-10</sup>.\nThe anti-IL-6 activity of the anti-IL-6 antibodies bind to IL-6 with an off-rate of less than or equal to 10<sup>-4</sup> S<sup>-1</sup>, 5x10<sup>-5</sup> S<sup>-1</sup>, 10<sup>-5</sup> S<sup>-1</sup>, 5x10<sup>-6</sup> S<sup>-1</sup>, 10<sup>-6</sup> S<sup>-1</sup>, 5x10<sup>-7</sup> S<sup>-1</sup>, or 10<sup>-7</sup> S<sup>-1</sup>."
    },
    {
        "molecule_name": "Interleukin 6",
        "protein_target_name": "IL-6",
        "binding_metric": "off-rate",
        "value": "<=5x10^-6",
        "unit": "S^-1",
        "is_logarithmic": false,
        "raw_mentions": "In one embodiment of the invention, the anti-IL-6 antibodies used in the present invention, bind to IL-6 with a dissociation constant (K<sub>D</sub>) of less than or equal to 5x10<sup>-7</sup>, 10<sup>-7</sup>, 5x10<sup>-8</sup>, 10<sup>-8</sup>, 5x10<sup>-9</sup>, 10<sup>-9</sup>, 5x10<sup>-10</sup>, 10<sup>-10</sup>, 5x10<sup>-11</sup>, 10<sup>-11</sup>, 5x10<sup>-12</sup>, 10<sup>-12</sup>, 5x10<sup>-13</sup>, 10<sup>-13</sup>, 5x10<sup>-14</sup>, 10<sup>-14</sup>, 5x10<sup>-15</sup> or 10<sup>-15</sup>.\nPreferably, the anti-IL-6 antibodies bind IL-6 with a dissociation constant of less than or equal to 5x10<sup>-10</sup>.\nThe anti-IL-6 activity of the anti-IL-6 antibodies bind to IL-6 with an off-rate of less than or equal to 10<sup>-4</sup> S<sup>-1</sup>, 5x10<sup>-5</sup> S<sup>-1</sup>, 10<sup>-5</sup> S<sup>-1</sup>, 5x10<sup>-6</sup> S<sup>-1</sup>, 10<sup>-6</sup> S<sup>-1</sup>, 5x10<sup>-7</sup> S<sup>-1</sup>, or 10<sup>-7</sup> S<sup>-1</sup>."
    },
    {
        "molecule_name": "Interleukin 6",
        "protein_target_name": "IL-6",
        "binding_metric": "off-rate",
        "value": "<=10^-6",
        "unit": "S^-1",
        "is_logarithmic": false,
        "raw_mentions": "In one embodiment of the invention, the anti-IL-6 antibodies used in the present invention, bind to IL-6 with a dissociation constant (K<sub>D</sub>) of less than or equal to 5x10<sup>-7</sup>, 10<sup>-7</sup>, 5x10<sup>-8</sup>, 10<sup>-8</sup>, 5x10<sup>-9</sup>, 10<sup>-9</sup>, 5x10<sup>-10</sup>, 10<sup>-10</sup>, 5x10<sup>-11</sup>, 10<sup>-11</sup>, 5x10<sup>-12</sup>, 10<sup>-12</sup>, 5x10<sup>-13</sup>, 10<sup>-13</sup>, 5x10<sup>-14</sup>, 10<sup>-14</sup>, 5x10<sup>-15</sup> or 10<sup>-15</sup>.\nPreferably, the anti-IL-6 antibodies bind IL-6 with a dissociation constant of less than or equal to 5x10<sup>-10</sup>.\nThe anti-IL-6 activity of the anti-IL-6 antibodies bind to IL-6 with an off-rate of less than or equal to 10<sup>-4</sup> S<sup>-1</sup>, 5x10<sup>-5</sup> S<sup>-1</sup>, 10<sup>-5</sup> S<sup>-1</sup>, 5x10<sup>-6</sup> S<sup>-1</sup>, 10<sup>-6</sup> S<sup>-1</sup>, 5x10<sup>-7</sup> S<sup>-1</sup>, or 10<sup>-7</sup> S<sup>-1</sup>."
    },
    {
        "molecule_name": "Interleukin 6",
        "protein_target_name": "IL-6",
        "binding_metric": "off-rate",
        "value": "<=5x10^-7",
        "unit": "S^-1",
        "is_logarithmic": false,
        "raw_mentions": "In one embodiment of the invention, the anti-IL-6 antibodies used in the present invention, bind to IL-6 with a dissociation constant (K<sub>D</sub>) of less than or equal to 5x10<sup>-7</sup>, 10<sup>-7</sup>, 5x10<sup>-8</sup>, 10<sup>-8</sup>, 5x10<sup>-9</sup>, 10<sup>-9</sup>, 5x10<sup>-10</sup>, 10<sup>-10</sup>, 5x10<sup>-11</sup>, 10<sup>-11</sup>, 5x10<sup>-12</sup>, 10<sup>-12</sup>, 5x10<sup>-13</sup>, 10<sup>-13</sup>, 5x10<sup>-14</sup>, 10<sup>-14</sup>, 5x10<sup>-15</sup> or 10<sup>-15</sup>.\nPreferably, the anti-IL-6 antibodies bind IL-6 with a dissociation constant of less than or equal to 5x10<sup>-10</sup>.\nThe anti-IL-6 activity of the anti-IL-6 antibodies bind to IL-6 with an off-rate of less than or equal to 10<sup>-4</sup> S<sup>-1</sup>, 5x10<sup>-5</sup> S<sup>-1</sup>, 10<sup>-5</sup> S<sup>-1</sup>, 5x10<sup>-6</sup> S<sup>-1</sup>, 10<sup>-6</sup> S<sup>-1</sup>, 5x10<sup>-7</sup> S<sup>-1</sup>, or 10<sup>-7</sup> S<sup>-1</sup>."
    },
    {
        "molecule_name": "Interleukin 6",
        "protein_target_name": "IL-6",
        "binding_metric": "off-rate",
        "value": "<=10^-7",
        "unit": "S^-1",
        "is_logarithmic": false,
        "raw_mentions": "In one embodiment of the invention, the anti-IL-6 antibodies used in the present invention, bind to IL-6 with a dissociation constant (K<sub>D</sub>) of less than or equal to 5x10<sup>-7</sup>, 10<sup>-7</sup>, 5x10<sup>-8</sup>, 10<sup>-8</sup>, 5x10<sup>-9</sup>, 10<sup>-9</sup>, 5x10<sup>-10</sup>, 10<sup>-10</sup>, 5x10<sup>-11</sup>, 10<sup>-11</sup>, 5x10<sup>-12</sup>, 10<sup>-12</sup>, 5x10<sup>-13</sup>, 10<sup>-13</sup>, 5x10<sup>-14</sup>, 10<sup>-14</sup>, 5x10<sup>-15</sup> or 10<sup>-15</sup>.\nPreferably, the anti-IL-6 antibodies bind IL-6 with a dissociation constant of less than or equal to 5x10<sup>-10</sup>.\nThe anti-IL-6 activity of the anti-IL-6 antibodies bind to IL-6 with an off-rate of less than or equal to 10<sup>-4</sup> S<sup>-1</sup>, 5x10<sup>-5</sup> S<sup>-1</sup>, 10<sup>-5</sup> S<sup>-1</sup>, 5x10<sup>-6</sup> S<sup>-1</sup>, 10<sup>-6</sup> S<sup>-1</sup>, 5x10<sup>-7</sup> S<sup>-1</sup>, or 10<sup>-7</sup> S<sup>-1</sup>."
    },
    {
        "molecule_name": "Interleukin-6",
        "protein_target_name": "A2M",
        "binding_metric": "IC50",
        "value": "0.1",
        "unit": "mg/kg",
        "is_logarithmic": false,
        "raw_mentions": "The IC50 for antibody Ab1 was 0.1 mg/kg with complete suppression of the A2M response at the 0.3 mg/kg. \nHuman IL-6 can provoke an acute phase response in rats, and one of the major acute phase proteins that is stimulated in the rat is α-2 macroglobulin (A2M) with plasma concentration of human IL-6 in these animals is very high at around 10ng/ml. \nRXF393 secretes human IL-6 and the plasma concentration of human IL-6 in these animals is very high at around 10ng/ml."
    },
    {
        "molecule_name": "Interleukin-6",
        "protein_target_name": "human IL-6",
        "binding_metric": "Kd",
        "value": "4",
        "unit": "pM",
        "is_logarithmic": false,
        "raw_mentions": "Here are the extracted sentences that meet the criteria:\n\n1. The dissociation constant for human IL-6 was 4 pM, indicating very high affinity.\n2. The dissociation constants of Ab1 for IL-6 of cynomolgus monkey, rat, and mouse were 31 pM, 1.4 nM, and 0.4 nM, respectively.\n3. Ab1 affinity for dog IL-6 below the limit of quantitation of the experiment is not included as it does not have a specific numeric value.\n4. Inhibition was consistent with the measured dissociation constants, but the specific IC50 values are not provided in this sentence, however, it is mentioned that \"the concentration at which Ab1 could inhibit 50% of proliferation (IC50) was measured\" which implies that the IC50 values are available, but not provided in this text snippet. \n\nNote that there are limited sentences that meet the criteria, as most of the text describes methods and experiments without providing specific numeric values for bioactivity metrics."
    },
    {
        "molecule_name": "Interleukin-6",
        "protein_target_name": "IL-6 of cynomolgus monkey",
        "binding_metric": "Kd",
        "value": "31",
        "unit": "pM",
        "is_logarithmic": false,
        "raw_mentions": "Here are the extracted sentences that meet the criteria:\n\n1. The dissociation constant for human IL-6 was 4 pM, indicating very high affinity.\n2. The dissociation constants of Ab1 for IL-6 of cynomolgus monkey, rat, and mouse were 31 pM, 1.4 nM, and 0.4 nM, respectively.\n3. Ab1 affinity for dog IL-6 below the limit of quantitation of the experiment is not included as it does not have a specific numeric value.\n4. Inhibition was consistent with the measured dissociation constants, but the specific IC50 values are not provided in this sentence, however, it is mentioned that \"the concentration at which Ab1 could inhibit 50% of proliferation (IC50) was measured\" which implies that the IC50 values are available, but not provided in this text snippet. \n\nNote that there are limited sentences that meet the criteria, as most of the text describes methods and experiments without providing specific numeric values for bioactivity metrics."
    },
    {
        "molecule_name": "Interleukin-6",
        "protein_target_name": "IL-6 of rat",
        "binding_metric": "Kd",
        "value": "1.4",
        "unit": "nM",
        "is_logarithmic": false,
        "raw_mentions": "Here are the extracted sentences that meet the criteria:\n\n1. The dissociation constant for human IL-6 was 4 pM, indicating very high affinity.\n2. The dissociation constants of Ab1 for IL-6 of cynomolgus monkey, rat, and mouse were 31 pM, 1.4 nM, and 0.4 nM, respectively.\n3. Ab1 affinity for dog IL-6 below the limit of quantitation of the experiment is not included as it does not have a specific numeric value.\n4. Inhibition was consistent with the measured dissociation constants, but the specific IC50 values are not provided in this sentence, however, it is mentioned that \"the concentration at which Ab1 could inhibit 50% of proliferation (IC50) was measured\" which implies that the IC50 values are available, but not provided in this text snippet. \n\nNote that there are limited sentences that meet the criteria, as most of the text describes methods and experiments without providing specific numeric values for bioactivity metrics."
    },
    {
        "molecule_name": "Interleukin-6",
        "protein_target_name": "IL-6 of mouse",
        "binding_metric": "Kd",
        "value": "0.4",
        "unit": "nM",
        "is_logarithmic": false,
        "raw_mentions": "Here are the extracted sentences that meet the criteria:\n\n1. The dissociation constant for human IL-6 was 4 pM, indicating very high affinity.\n2. The dissociation constants of Ab1 for IL-6 of cynomolgus monkey, rat, and mouse were 31 pM, 1.4 nM, and 0.4 nM, respectively.\n3. Ab1 affinity for dog IL-6 below the limit of quantitation of the experiment is not included as it does not have a specific numeric value.\n4. Inhibition was consistent with the measured dissociation constants, but the specific IC50 values are not provided in this sentence, however, it is mentioned that \"the concentration at which Ab1 could inhibit 50% of proliferation (IC50) was measured\" which implies that the IC50 values are available, but not provided in this text snippet. \n\nNote that there are limited sentences that meet the criteria, as most of the text describes methods and experiments without providing specific numeric values for bioactivity metrics."
    }
]